[In Context] Preparing for disease-modifying therapies in Alzheimer’s disease

The long-awaited era of disease-modifying therapy for Alzheimer’s disease has finally arrived and will substantially impact how the disease is perceived and managed, although these new treatments will pose challenges for equitable access. The drugs closest to widespread clinical implementation are lecanemab and donanemab—intravenous monoclonal antibodies that remove β-amyloid plaques from the brain and can… Continue reading [In Context] Preparing for disease-modifying therapies in Alzheimer’s disease

Unrelated or haploidentical allogeneic hematopoietic cell transplantation in second complete remission for acute myeloid leukemia—Improved outcomes over time: A European Society for Blood and Marrow Transplantation Acute Leukemia Working Party study

Allogeneic hematopoietic cell transplantation (allo-HCT) is the only cure for acute myeloid leukemia (AML) in second complete remission (CR2) Patients lacking a matched sibling donor (MSD) receive transplants from mismatched unrelated donors .

Four researchers with MIT ties earn 2023 Schmidt Science Fellowships

AI SummaryFour researchers with ties to MIT have been named Schmidt Science Fellows. Lillian Chin, Neil Dalvie, Suong Nguyen, and Yirui Zhang are among the 32 exceptional early-career scientists worldwide chosen to receive the prestigious fellowships. They will receive a stipend of $100,000 a year for up to two years of postdoctoral research in a… Continue reading Four researchers with MIT ties earn 2023 Schmidt Science Fellowships